文拉法辛与米氮平治疗老年抑郁症的临床研究

Venlafaxine vs. Mirtazapine for Depression in Old Age:a Clinical Study

目的:比较文拉法辛与米氮平治疗老年期抑郁症的疗效和安全性。方法:将103例60岁以上的抑郁症患者随机分为治疗组(文拉法辛组,53例)、对照组(米氮平组,50例),疗程均为8周。分别于治疗前及治疗后第1、2、4、8周末使用汉密尔顿抑郁量表(HAMD)17项、生活质量综合评定问卷、副反应量表(TESS)评价临床疗效、生活质量和不良反应。结果:两组均完成治疗,治疗组和对照组有效率分别为92.5%和90.0%,两组患者疗效差异无统计学意义(P>0.05),两组患者均未出现严重的不良反应。结论:米氮平与文拉法辛用于治疗老年抑郁症疗效与安全性相当,均可作为治疗抑郁症的一线药物。

OBJECTIVE：To evaluate the clinical efficacy and safety of venlafaxine vs. mirtazapine in the treatment of depres-sion in old age. METHODS：A total of 103 patients aged above 60 years with depression were randomly assigned to either treat-ment group receiving venlafaxine （53 cases） or control group receiving mirtazapine （50 cases） for treatment of 8 weeks. Before treatment and at 0,1,2,4 and 8 weeks of treatment,the clinical efficacy,quality of life and adverse effects were evaluated using Hamilton depression scale（HAMD）（17 items）,Generic Quality of life Inventory（GQOLI）and side effects scale（TESS）respec-tively. RESULTS：All patients completed the treatment;the effective rate in the treatment group vs. control group was 92.5% vs. 90.0%（P〉0.05）;serious adverse reactions were noted in none of groups. CONCLUSIONS：Mirtazapine is as effective and safe as venlafaxine for depression in old age thus both can be used as the first-line drug for the treatment of depression.